Related Experiment Video

Updated: Nov 14, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

607

Nanocarrier-delivered small interfering RNA for chemoresistant ovarian cancer therapy

Mingyuan Zou1, Yue Du2, Ruizhen Liu3

  • 1Medical School of Southeast University, Nanjing, Jiangsu, China.

Wiley Interdisciplinary Reviews. RNA
|March 8, 2021
PubMed

Insights

Ovarian cancer patients often develop treatment resistance, leading to poor outcomes. This review explores nanocarrier-delivered small interfering RNA (siRNA) as a potential therapy to overcome chemotherapy resistance and improve survival rates.

Area of Science:

  • Biomedical Science
  • Oncology
  • RNA Nanotechnology

Background:

  • Ovarian cancer is a leading cause of cancer death in women, with limited early screening success.
  • Advanced ovarian cancer frequently develops resistance to multiple treatments, resulting in a poor prognosis.
  • Recurrence remains a significant challenge despite surgery and chemotherapy, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To analyze molecular mechanisms underlying chemotherapy resistance in ovarian cancer.
  • To discuss the potential of nanocarrier-delivered small interfering RNA (siRNA) for treating chemotherapy-resistant ovarian cancer.
  • To encourage collaborative research on nanocarrier-siRNA for improved patient survival and quality of life.

Main Methods:

  • Review of existing literature on ovarian cancer pathogenesis and chemotherapy resistance.
  • Analysis of molecular mechanisms contributing to treatment resistance.
  • Evaluation of nanocarrier-delivered siRNA technology for therapeutic applications.

Main Results:

  • Chemotherapy resistance in ovarian cancer is driven by complex molecular mechanisms.
  • Nanocarrier-delivered siRNA presents a promising approach to target and overcome these resistance mechanisms.
  • Further research and clinical studies are needed to optimize nanocarrier-siRNA delivery and efficacy.

Conclusions:

  • Understanding molecular mechanisms of resistance is crucial for developing effective ovarian cancer treatments.
  • Nanocarrier-delivered siRNA holds significant potential for overcoming chemotherapy resistance and improving patient outcomes.
  • Collaborative efforts in nanocarrier-siRNA research are essential to enhance long-term survival and quality of life for ovarian cancer patients.
Keywords:
chemotherapy resistancenanocarrierovarian cancersmall interfering RNAtargeted therapy

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

8.4K

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.8K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.6K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.1K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K